Volume 3.23 | Jun 18

Cancer Stem Cell News 3.23 June 18, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy
When engrafted leukemic cells substantially damaged adjacent microenvironment in the bone marrow, after chemotherapy small foci of cancer-propagating cells were retained, surrounded by sheaths of supporting cells that comprise a protective niche. [Cancer Cell] Abstract
ISSCR 2014: Our City. Our Science. Visit us at Booth #817
 
PUBLICATIONS (Ranked by impact factor of the journal)
CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer
Researchers investigated the generation of polyploid giant cancer cells in colon cancer cells and identified mechanisms of formation. Treatment of HCT-116 and Caco-2 colon cancer cells with the hypoxia mimic cobalt chloride (CoCl2) induced the formation of cells with larger cell and nuclear size, while the cells with normal morphology were selectively eliminated. [PLoS One] Full Article

Establishment of Highly Tumorigenic Human Colorectal Cancer Cell Line (CR4) with Properties of Putative Cancer Stem Cells
Researchers report the establishment of a novel cancer-initiating cell-enriched, highly tumorigenic and clonogenic colon cancer cell line, CR4, derived from liver metastasis. [PLoS One] Full Article

Knockdown of miR-210 Decreases Hypoxic Glioma Stem Cells Stemness and Radioresistance
To explore the possibility of miR-210 as an effective therapeutic target to hypoxic glioma stem cells, scientists employed lentiviral-mediated anti-sense miR-210 gene transfer technique to knockdown miR-210 expression and analyze phenotypic changes in hypoxic U87s and SHG44s cells. [Exp Cell Res] Abstract

Cancer Stem Cell Phenotype Is Supported by Secretory Phospholipase A2 in Human Lung Cancer Cells
Viral knockdown and chemical inhibition of secretory phospholipase A2 group IIa (sPLA2) reduce tumorsphere formation in lung cancer cells demonstrate for the first time that sPLA2 plays an important role in cancer stem cells. [Ann Thorac Surg] Abstract

QKI Impairs Self-Renewal and Tumorigenicity of Oral Cancer Cells via Repression of SOX2
Researchers showed that reduced Quaking (QKI) levels were observed in many human oral cancer samples. Moreover further reduction of QKI expression in cancer stem cells (CSCs) was detected compared with non-CSCs in oral cancer cell lines. [Cancer Biol Ther] Full Article

Characterization of Side Population Cells Isolated from the Colon Cancer Cell Line SW480
The self-renewal, differentiated progeny, clone formation, proliferation, invasion ability, cell cycle, chemosensitivity and tumorigenic properties in side population (SP) and non-SP cells were investigated through in vitro culture and in vivo serial transplantation. [Int J Oncol] Abstract

Resistance of Oral Squamous Cell Carcinoma Cells to Cetuximab Is Associated with EGFR Insensitivity and Enhanced Stem Cell-Like Potency
Researchers characterized cetuximab-resistant oral squamous cell carcinoma (OSCC) cell lines. The human OSCC cell lines HSC3, HSC4 and SAS were used. Cetuximab-resistant SAS cells not only engaged in epidermal growth factor receptor (EGFR)-independent growth but also exhibited stem cell-like properties. [Oncol Rep] Abstract

Cancer Stem Cell Differentiation: TGFβ1 and Versican May Trigger Molecules for the Organization of Tumor Spheroids
Scientists constructed an in vitro differentiation model for cancer stem cells (CSCs). CSCs isolated and proliferated for one passage were maintained as monolayers or spheroid-forming cells with serum included media for differentiation process. [Oncol Rep] Abstract

Heading to ISSCR 2014 in Vancouver?
Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!

Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)
 
REVIEWS
Stem Cell Dynamics in Homeostasis and Cancer of the Intestine
Intestinal stem cells (ISCs) and colorectal cancer (CRC) biology are tightly linked in many aspects. It is generally thought that ISCs are the cells of origin for a large proportion of CRCs and crucial ISC-associated signaling pathways are often affected in CRCs. Moreover, CRCs are thought to retain a cellular hierarchy that is reminiscent of the intestinal epithelium. [Nat Rev Cancer] Abstract

Epigenetic Mechanisms of Tumorigenicity Manifesting in Stem Cells
The cancer-related epigenetic mechanisms found in pluripotent stem cells and cancer cells are discussed, focusing on both the similarities and the differences. [Oncogene] Abstract

Targeting the NF-E2-Related Factor 2 Pathway: A Novel Strategy for Glioblastoma
The authors discuss a novel framework of nuclear factor erythroid 2-related factor 2 (Nrf2) in the regulation of glioblastoma and the mechanisms regarding the downregulation of Nrf2 in treating glioblastoma. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
SCIENCE NEWS
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed against Chemo-Resistant Ovarian Cancer Stem Cells
Novogen Limited and CanTx Inc. announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. [Press release from Novogen Limited discussing research presented at the Drug Discovery and Therapy 2014 World Congress, Boston] Press Release

ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
ImmunoGen, Inc. disclosed for the first time preclinical data for IMGN779. IMGN779 is a novel, CD33-targeting, DNA-alkylating antibody-drug conjugate that is a potential treatment for acute myeloid leukemia. [Press release from ImmunoGen, Inc. discussing research presented at the 19th Congress of the European Hematology Association (EHA), Milan] Press Release

Boston Biomedical Announces Clinical Data Presentation of Its Cancer Stem Cell Inhibitor Programs
Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by Boston Biomedical. [Press release from Boston Biomedical discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) 50th Annual Meeting, Chicago] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
INDUSTRY NEWS
Amgen Joins the National Cancer Institute and Research Partners to Help Accelerate Development of Personalized Treatment Approaches for Squamous Cell Lung Cancer
Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol, a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. [Amgen, Inc.] Press Release

Western Oncolytics Receives $275,000 Seed Funding for Development of Cancer Immunotherapy
Western Oncolytics Ltd. has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells. [PR Newswire Association LLC] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Best of American Society of Clinical Oncology (ASCO) Chicago Meeting
August 15-16, 2014
Chicago, United States

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Research Assistant/Research Associate – Stem Cell and Cancer Biology (University of North Texas Health Science Center)

NEW Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

NEW Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

Research Officers – Cancer Stem Cell Biology (Genome Institute of Singapore)

PhD Scholarship – Inorganic Nanoparticles for Cancer Stem Cell Targeting and Detection (The Italian Institute of Technology)

Positions for Principal Investigators – Translational Medical Research of Cancer Biology (Shanghai Institute of Biochemistry and Cell Biology)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health and Science University)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us